Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines

NCT05335499 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05335499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2022
Completion date
December 22, 2023
Enrollment
126 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria